Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines

Molecular Immunology

Volumn 46, Issue 15, 2009, Pages 2931-2937

  Antwi, Kwasi ^a   Hanavan, Paul D ^a   Myers, Cheryl E ^a   Ruiz, Yvette W ^a   Thompson, Eric J ^b   Lake, Douglas F ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b Caris MPI   (United States)

Author keywords

Cell line; Immune system; Liquid chromatography; Major histocompatibility complex; Mass spectrometry; MHC refolding assay; Peptides

Indexed keywords

BUFFER; CITRIC ACID; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; SYNTHETIC PEPTIDE;

ACIDITY; AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; ELUTION; HLA SYSTEM; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREAS CANCER; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEOMICS; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTICOAGULANTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRIC ACID; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDROGEN-ION CONCENTRATION; PANCREATIC NEOPLASMS; PAPAIN; PEPTIDE FRAGMENTS; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 68749110478     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.06.021     Document Type: Article

References (27)

1. Dionne S.O., Lake D.F., Grimes W.J., and Smith M.H. Identification of HLA-Cw6.02 and HLA-Cw7. 01 allele-specific binding motifs by screening synthetic peptide libraries. Immunogenetics 56 (2004) 391-398
2. Dionne S.O., Myers C.E., Smith M.H., and Lake D.F. Her-2/neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction. Cancer Immunol. Immunother. 53 (2004) 307-314
3. Emberley E.D., Murphy L.C., and Watson P.H. S100 proteins and their influence on pro-survival pathways in cancer. Biochem. Cell Biol. 82 (2004) 508-515
4. Falk C.S., and Schendel D.J. HLA-C revisited. Ten years of change. Immunol. Res. 16 (1997) 203-214
5. Galati G., Arcelloni C., Paroni R., Heltai S., Rovere P., Rugarli C., and Manfredi A.A. Quantitative cytometry of MHC class I digestion from living cells. Cytometry 27 (1997) 77-83
6. Gebreselassie D., Spiegel H., and Vukmanovic S. Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum. Immunol. 67 (2006) 894-906
7. Gillies R.J., Robey I., and Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 49 Suppl. 2 (2008) 24S-42S
8. Hawkins O.E., Vangundy R.S., Eckerd A.M., Bardet W., Buchli R., Weidanz J.A., and Hildebrand W.H. Identification of breast cancer peptide epitopes presented by HLA-A*0201. J. Proteome Res. 7 (2008) 1445-1457
9. Kessler J.H., Mommaas B., Mutis T., Huijbers I., Vissers D., Benckhuijsen W.E., Schreuder G.M., Offringa R., Goulmy E., Melief C.J., van der Burg S.H., and Drijfhout J.W. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum. Immunol. 64 (2003) 245-255
10. Kim J., Yoon S., Joo J., Lee Y., Lee K., Chung J., and Choe I. S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol. Res. 23 (2002) 274
11. Kisselev A.F., Akopian T.N., and Goldberg A.L. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J. Biol. Chem. 273 (1998) 1982-1989
12. Kisselev A.F., Akopian T.N., Woo K.M., and Goldberg A.L. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274 (1999) 3363-3371
13. Klammer A.A., and MacCoss M.J. Effects of modified digestion schemes on the identification of proteins from complex mixtures. J. Proteome Res. 5 (2006) 695-700
14. Komatsu K., Andoh A., Ishiguro S., Suzuki N., Hunai H., Kobune-Fujiwara Y., Kameyama M., Miyoshi J., Akedo H., and Nakamura H. Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin .Cancer Res. 6 (2000) 172-177
15. Komatsu K., Kobune-Fujiwara Y., Andoh A., Ishiguro S., Hunai H., Suzuki N., Kameyama M., Murata K., Miyoshi J., Akedo H., Tatsuta M., and Nakamura H. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br. J. Cancer 83 (2000) 769-774
16. Maelandsmo G.M., Florenes V.A., Mellingsaeter T., Hovig E., Kerbel R.S., and Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int. J. Cancer 74 (1997) 464-469
17. Mo X.Y., Cascio P., Lemerise K., Goldberg A.L., and Rock K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 163 (1999) 5851-5859
18. Parham P., Barnstable C.J., and Bodmer W.F. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C, antigens. J. Immunol. 123 (1979) 342-349
19. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., and Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157 (1996) 2539-2548
20. Rock K.L., and Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17 (1999) 739-779
21. Schuler M.M., Nastke M.D., and Stevanovikc S. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol. Biol. 409 (2007) 75-93
22. Smith M.H., Lam K.S., Hersh E.M., Lebl M., and Grimes W.J. Baculoviral expressed HLA class I heavy chains used to screen a sythetic peptide library for allele-specific peptide motifs. Mol. Immunol. 35 (1998) 1033-1043
23. Stryhn A., Pedersen L.O., Holm A., and Buus S. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur. J. Immunol. 30 (2000) 3089-3099
24. van der Burg S.H., Ras E., Drijfhout J.W., Benckhuijsen W.E., Bremers A.J., Melief C.J., and Kast W.M. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum. Immunol. 44 (1995) 189-198
25. York I.A., Bhutani N., Zendzian S., Goldberg A.L., and Rock K.L. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J. Immunol. 177 (2006) 1434-1443
26. York I.A., Brehm M.A., Zendzian S., Towne C.F., and Rock K.L. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 9202-9207
27. Zemmour J., and Parham P. Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C. J. Exp. Med. 176 (1992) 937-950